Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 113-122

  Rubinson, Douglas A ^a   Hochster, Howard S ^b   Ryan, David P ^c   Wolpin, Brian M ^a   McCleary, Nadine Jackson ^a   Abrams, Thomas A ^a   Chan, Jennifer A ^a   Iqbal, Syma ^d   Lenz, Heinz J ^d   Lim, Dean ^e   Rose, Jeffrey ^f   Bekaii Saab, Tanios ^g   Chen, Helen X ^h   Fuchs, Charles S ^a   Ng, Kimmie ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b YALE CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f Lowcountry Hematology and Oncology   (United States)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; Colorectal Cancer; Pertuzumab; Phase I; Phase II

Indexed keywords

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84899066658     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9956-5     Document Type: Article

References (35)

1. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol: J American Soc Clin Oncol 22(7):1201-1208. doi:10.1200/JCO.2004.10.182
2. Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, Bosch A, Cervantes A (2008) Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 99(3):455-458. doi:10.1038/sj.bjc.6604530
3. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 27(5):663-671. doi:10.1200/JCO.2008.20.8397
4. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408-1417. doi:10.1056/NEJMoa0805019
5. Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 30(23):2861-2868. doi:10.1200/JCO.2011.40.9243
6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 26(10):1626-1634. doi:10.1200/JCO.2007.14.7116
7. Baselga J, Rosen N (2008) Determinants of RASistance to antiepidermal growth factor receptor agents. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 26(10):1582-1584. doi:10.1200/JCO.2007.15.3700
8. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, Investigators MCT (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103-2114. doi:10.1016/S0140-6736(11)60613-2
9. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537-540. doi:10.1038/nature11219
10. Oliveras-Ferraros C, Massaguer Vall-Llovera A, Vazquez-Martin A, Salip DC, Queralt B, Cufi S, Martin-Castillo B, Bosch-Barrera J, Brunet J, De Llorens R, Menendez JA (2012) Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. Oncol Rep 27(6):1887-1892. doi:10.3892/or.2012.1732
11. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L (2011) A molecularly annotated platform of patientderived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6):508-523. doi:10.1158/2159-8290.CD-11-0109
12. Quesnelle KM, Grandis JR (2011) Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res: J American Assoc Cancer Res 17(18):5935-5944. doi:10.1158/1078-0432.CCR-11-0370
13. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2):127-137
14. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 24(26):4324-4332. doi:10.1200/JCO.2005.05. 4221
15. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Strauss A, Kelsey S, Sliwkowski MX, Matulonis U (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 28(7):1215-1223. doi:10.1200/JCO.2009.22.3354
16. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, Group CS (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109-119. doi:10.1056/NEJMoa1113216
17. Pohl M, Stricker I, Schoeneck A, Schulmann K, Klein-Scory S, Schwarte-Waldhoff I, Hasmann M, Tannapfel A, Schmiegel W, Reinacher-Schick A (2009) Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 135(10):1377-1386. doi:10.1007/s00432-009-0579-3
18. Felip E, Ranson M, Cedres S, Dean E, Brewster M, Martinez P, McNally V, Ross G, Galdermans D (2012) A phase Ib, dosefinding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. doi:10.1016/j.cllc.2012.03.004
19. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC (2012) Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 30(13):1505-1512. doi:10.1200/JCO.2011.38.6599
20. Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37(1):1-3. doi:10.1002/mpo.1154
21. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. Journal of Clinical Oncology: official Journal of the American Society of Clinical Oncology 23(11):2534-2543. doi:10.1200/JCO.2005.03. 184
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
23. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773-1782
24. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532-536. doi:10.1038/nature11156
25. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Janne PA (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3(99):99ra86. doi:10.1126/scitranslmed.3002442
26. Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG (2006) Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66(1):404-411. doi:10.1158/0008-5472.CAN-05-2506
27. Fields AL, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, Leopold LH, Berger MS (2005) An open-label multicenter phase ii study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 23(16S):1
28. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S (2004) Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Investigation 22(6):858-865
29. Clark JW, Niedzwiecki, D., Hollis, D., Mayer, R., Cancer and Leukemia Group B Phase II trial of 5-fluorouracil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. In: 2003 ASCO Annual Meeting, Chicago, IL, 2003. ASCO
30. Takahashi T, Boku N, Murakami H, Naito T, Tsuya A, Nakamura Y, Ono A, Machida N, Yamazaki K, Watanabe J, Ruiz-Garcia A, Imai K, Ohki E, Yamamoto N (2012) Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigational New Drugs. doi:10.1007/s10637-011-9789-z
31. Su X, Lacouture ME, Jia Y, Wu S (2009) Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and metaanalysis. Oncology 77(2):124-133. doi:10.1159/000229752
32. Drucker AM, Wu S, Dang CT, Lacouture ME (2012) Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a metaanalysis. Breast Cancer Research and Treatment. doi:10.1007/s10549-012-2157-7
33. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345. doi:10.1056/NEJMoa033025
34. Laux I, Jain A, Singh S, Agus DB (2006) Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 94(1):85-92. doi:10.1038/sj.bjc.6602875
35. De Potter IY, Poumay Y, Squillace KA, Pittelkow MR (2001) Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Experimental Cell Research 271(2):315-328. doi:10.1006/excr.2001.5390